Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 200

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

Open access
Anagnostou, Valsamo, Niknafs, Noushin, Marrone, Kristen, Bruhm, Daniel C., White, James R., Naidoo, Jarushka, Hummelink, Karlijn, Monkhorst, Kim, Lalezari, Ferry, Lanis, Mara, Rosner, Samuel, Reuss, Joshua E., Smith, Kellie N., Adleff, Vilmos, Rodgers, Kristen, Belcaid, Zineb, Rhymee, Lamia, Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Ettinger, David S., Georgiades, Christos, Verde, Franco, Illei, Peter, Li, Qing Kay, Baras, Alexander S., Gabrielson, Edward, Brock, Malcolm V., Karchin, Rachel, Pardoll, Drew M., Baylin, Stephen B., Brahmer, Julie R., Scharpf, Robert B., Forde, Patrick M., Velculescu, Victor E. · 2020 · Nature Cancer

Abstract

Despite progress in immunotherapy, identifying patients that respond has remained a challenge. Through analysis of whole-exome and targeted sequence data from 5,449 tumors, we found a significant correlation between tumor mutation burden (TMB) and tumor purity, suggesting that low tumor purity tumors are likely to have inaccurate TMB estimates. We developed a new method to estimate a corrected TMB (cTMB) that was adjusted for tumor purity and more accurately predicted outcome to immune checkpoint blockade (ICB). To identify improved predictive markers together with cTMB, we performed whole-exome sequencing for 104 lung tumors treated with ICB. Through comprehensive analyses of sequence and structural alterations, we discovered a significant enrichment in activating mutations in receptor tyrosine kinase (RTK) genes in nonresponding tumors in three immunotherapy treated cohorts. An integrated multivariable model incorporating cTMB, RTK mutations, smoking-related mutational signature and human leukocyte antigen status provided an improved predictor of response to immunotherapy that was independently validated. Anagnostou et al. present an improved predictor of response to immune checkpoint blockade that integrates estimates of tumor mutational burden corrected for tumor purity, RTK genomic alterations, a smoking-related mutational signature and HLA status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-019-0008-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 200

Metadata

Authors
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J. E., Smith, K. N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., Hann, C. L., Ettinger, D. S., Georgiades, C., Verde, F., Illei, P., Li, Q. K., Baras, A. S., Gabrielson, E., Brock, M. V., Karchin, R., Pardoll, D. M., Baylin, S. B., Brahmer, J. R., Scharpf, R. B., Forde, P. M., & Velculescu, V. E.
Venue
Nature Cancer
Published
2020-01-13
Volume
1
Issue
1
Pages
99-111
ISSN
2662-1347 (ISSN-L)
OpenAlex
W2999445610
Cited by
200
References
25
FWCI
11.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. https://app.cochat.ai/papers/10.1038/s43018-019-0008-8
The paper
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J. E., Smith, K. N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., . . . Velculescu, V. E. (2020). Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. https://doi.org/10.1038/s43018-019-0008-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.